COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET. The meeting will be held at the company’s offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. The agenda and proposals can be found on Evaxion’s website, along with other materials: www.evaxion.ai/investors/events-presentations/a ...

Core Viewpoint - Evaxion A/S is experiencing a slight delay in the filing and publication of its 2025 annual report due to unforeseen technical issues with external vendors, unrelated to the report's content [1][2]. Company Overview - Evaxion A/S is a clinical-stage TechBio company that utilizes its proprietary AI-Immunology™ platform to develop novel vaccines targeting cancer and infectious diseases [4][5]. - The company has a team of over 40 experts involved in the entire value chain from target discovery to clinical development [5]. Technical Issues - The technical issues causing the delay are related to regulatory filing demands and do not affect the report itself [2]. - The conference call and webcast originally scheduled for the day of the report's release have been rescheduled to the following day, March 6, at 8:30 ET / 14:30 CET [2]. Pipeline and Development - Evaxion has developed a clinical pipeline that includes both personalized and off-the-shelf cancer vaccine candidates, as well as prophylactic vaccine candidates for infectious diseases [5]. - The company's vaccine candidates aim to address high unmet medical needs, reflecting its commitment to innovative and targeted treatment options [5].

Core Insights - Evaxion A/S is set to provide a business update and report its full year 2025 financial results on March 5, 2026, before the opening of Nasdaq CM [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST to present the update and results, along with a Q&A session [1] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its proprietary AI-Immunology™ platform to develop novel vaccines targeting cancer and infectious diseases [3][4] - The AI-Immunology™ platform enables rapid and efficient target discovery, drug design, and development, supported by a team of over 40 experts [4] Product Pipeline - The company has developed a clinical pipeline that includes both personalized and off-the-shelf cancer vaccine candidates, as well as prophylactic vaccine candidates for infectious diseases [4] - All vaccine candidates aim to address high unmet medical needs, reflecting the company's commitment to transforming patients' lives through innovative treatment options [4]

Core Insights - Recursion, a clinical stage TechBio company, will provide business updates and report its fourth quarter and full year 2025 financial results on February 25, 2026, before the market opens [1] - The company will host a live earnings call on the same day at 8:00 am ET, allowing investors and the public to submit questions [2] Company Overview - Recursion is focused on decoding biology to improve lives, utilizing its Recursion OS platform to generate one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, operating at a scale of millions of wet lab experiments weekly [3] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, with additional offices in Montréal, New York, London, and the Oxford area [4]

Core Insights - Recursion, a clinical stage TechBio company, focuses on decoding biology to significantly enhance lives [1] - The CEO, Najat Khan, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - The company will also participate in the 28th Annual Needham Growth Conference on January 16, 2026 [1] Company Overview - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [2] - The company has additional offices in Montréal, New York, London, and the Oxford area [2] - Recursion utilizes a platform called Recursion OS, which generates one of the largest proprietary biological and chemical datasets globally [1] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [1] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world to advance medical research [1]

Group 1 - Recursion Pharmaceuticals, Inc. (RXRX) is identified as a TechBio company experiencing a rise in share price, increasing from approximately $4.5 in early October [1] - The article highlights the importance of staying updated on stocks within the biotech, pharma, and healthcare industries, emphasizing key trends and catalysts that drive valuations [1] - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, provides insights and forecasts for over 1,000 companies in the sector [1]

Core Insights - Recursion Pharmaceuticals, Inc. (RXRX) has seen a rise in share price, increasing from approximately $4.5 in early October, indicating positive market sentiment towards the company [1]. Company Overview - Recursion Pharmaceuticals is categorized as a TechBio company, focusing on biotechnology and healthcare sectors [1]. - The company is under the coverage of a biotech consultant with over five years of experience in the industry, who has analyzed more than 1,000 companies [1]. Investment Group Insights - The Haggerston BioHealth investing group provides resources for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, and detailed financial forecasts for major pharmaceutical companies [1]. - The group also offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis, which are essential for informed investment decisions in the biotech sector [1].

Core Insights - Recursion, a clinical stage TechBio company, will present new clinical data from the ongoing TUPELO Phase 1b/2 trial of REC-4881 for Familial Adenomatous Polyposis (FAP) during a webinar on December 8, 2025 [1][2] - The company utilizes a platform called Recursion OS, which integrates various technologies to create one of the largest proprietary biological and chemical datasets, enabling advanced drug discovery [3] Company Overview - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry, with additional offices in Montréal, New York, London, and Oxford [4] - The company focuses on decoding biology to improve lives, leveraging machine-learning algorithms to analyze vast datasets and conduct millions of wet lab experiments weekly [3] Leadership and Presenters - The webinar will feature key personnel including Najat Khan, Ph.D. (Chief R&D and Chief Commercial Officer), David Mauro, M.D., Ph.D. (Chief Medical Officer), and other notable experts [6]

Financial Status & Outlook - Recursion had approximately $785 million in cash as of October 9, 2025 [12, 72] - The company anticipates a cash runway through the end of 2027 without needing additional financing [12, 71] - Recursion projects its 2025 cash burn to be less than $450 million [73] - The company expects its 2026 cash burn to be less than $390 million [73] - Total cash inflows exceeding $500 million have been achieved across all partnerships and collaborations [15, 72] Pipeline & Platform Advancements - The company is anticipating multiple catalysts in the second half of 2025, including additional safety and efficacy data for REC-4881 in Familial Adenomatous Polyposis (FAP) [11, 79] - Recursion's platform has facilitated a $30 million milestone payment for delivering a second whole-genome neuro map [15, 72, 77] - In a Phase 1b/2 trial of REC-4881, 43% median reduction in total polyp burden was observed [61] - 6 out of 6 patients achieved >30% reduction in total polyp burden in REC-4881 Phase 1b/2 trial [62] - In Phase 1 monotherapy dose-escalation of REC-617, 90% of patients experienced treatment-related adverse events (TRAEs), with 28% being Grade ≥3 [48]

Core Insights - ClearBridge Investments reported a strong rebound in U.S. equities during Q2 2025, with the S&P 500 Index returning 10.9% and the Russell 3000 Index advancing 11.0% as risk-on sentiment increased following a pause in tariff implementation [1] - The ClearBridge Select Strategy outperformed its benchmark due to effective portfolio construction across various companies and sectors with distinct growth drivers [1] Company Highlights - Caris Life Sciences, Inc. (NASDAQ:CAI) is highlighted as a key stock in the ClearBridge Select Strategy, being an AI-driven TechBio company focused on cancer care and genetic profiling [2][3] - Caris Life Sciences experienced a one-month return of -12.04% but gained 19.75% over three months, closing at $33.53 per share with a market capitalization of $9.431 billion as of September 17, 2025 [2] - The company went public late in Q2 2025 and offers differentiated molecular profiling services to biopharmaceutical companies using machine learning algorithms [3] Hedge Fund Interest - Caris Life Sciences was held by 42 hedge fund portfolios at the end of Q2 2025, a significant increase from 0 in the previous quarter, indicating growing interest among institutional investors [4] - Despite the potential of Caris Life Sciences, the company is not listed among the 30 most popular stocks among hedge funds, with some analysts suggesting that other AI stocks may offer greater upside potential and less downside risk [4]